Serum lipidomics analysis of psoriasis patients receiving pretherapy and posttreatment with anti-IL-17A mAb showed that the treatment ameliorated the skin lesions and regulated the dysregulated metabolism of LCFAs. Here, IL17A is linked to psoriasis.